X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2188) 2188
Newspaper Article (54) 54
Newsletter (44) 44
Dissertation (41) 41
Magazine Article (27) 27
Book Chapter (23) 23
Conference Proceeding (3) 3
Publication (2) 2
Book Review (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
efavirenz (2140) 2140
science & technology (1375) 1375
life sciences & biomedicine (1195) 1195
humans (1125) 1125
hiv infections - drug therapy (788) 788
hiv (751) 751
male (714) 714
female (697) 697
adult (626) 626
infectious diseases (604) 604
human immunodeficiency virus--hiv (532) 532
pharmacology & pharmacy (452) 452
antiretroviral drugs (436) 436
antiviral agents (430) 430
antiretroviral therapy (399) 399
anti-hiv agents - therapeutic use (387) 387
immunology (381) 381
drug therapy (377) 377
middle aged (375) 375
nevirapine (352) 352
highly active antiretroviral therapy (347) 347
hiv infection (331) 331
aids/hiv (298) 298
benzoxazines - therapeutic use (278) 278
research (271) 271
antiretroviral agents (269) 269
tenofovir (266) 266
virology (263) 263
acquired immune deficiency syndrome--aids (248) 248
analysis (245) 245
health aspects (240) 240
treatment outcome (236) 236
aids (225) 225
benzoxazines - administration & dosage (218) 218
anti-hiv agents - adverse effects (216) 216
anti-hiv agents - administration & dosage (209) 209
emtricitabine (209) 209
virus diseases (209) 209
hiv infections - virology (208) 208
reverse transcriptase inhibitors - therapeutic use (205) 205
benzoxazines - adverse effects (203) 203
benzoxazines (200) 200
lamivudine (198) 198
patients (197) 197
viral load (193) 193
human immunodeficiency virus (189) 189
benzoxazines - pharmacokinetics (188) 188
drugs (188) 188
microbiology (187) 187
pharmacokinetics (186) 186
hiv-1 - drug effects (183) 183
dosage and administration (181) 181
hiv patients (178) 178
medicine (175) 175
young adult (173) 173
cd4 lymphocyte count (171) 171
drug therapy, combination (166) 166
hiv-1 (162) 162
research article (158) 158
risk factors (158) 158
cd4 antigen (157) 157
science & technology - other topics (152) 152
lopinavir (151) 151
drug resistance (150) 150
anti-hiv agents - pharmacokinetics (148) 148
care and treatment (147) 147
ritonavir (146) 146
adolescent (143) 143
acquired immune deficiency syndrome (141) 141
multidisciplinary sciences (140) 140
drug interactions (139) 139
science (135) 135
rna-directed dna polymerase (134) 134
protease inhibitors (132) 132
antiretroviral therapy, highly active (130) 130
reverse transcriptase inhibitors - adverse effects (130) 130
medical research (129) 129
tuberculosis (127) 127
clinical trials (126) 126
hiv infections - complications (126) 126
oxazines - therapeutic use (124) 124
mutation (119) 119
non-nucleoside reverse transcriptase inhibitors (119) 119
pharmacology (118) 118
zidovudine (118) 118
anti-hiv agents (116) 116
anti-hiv agents - pharmacology (116) 116
benzoxazines - pharmacology (116) 116
infections (116) 116
usage (116) 116
drug combinations (110) 110
genotype (107) 107
pregnancy (106) 106
viruses (106) 106
physical sciences (105) 105
prospective studies (105) 105
toxicity (104) 104
therapy (103) 103
animals (102) 102
aged (101) 101
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2304) 2304
Portuguese (39) 39
Spanish (26) 26
French (23) 23
German (9) 9
Japanese (6) 6
Chinese (3) 3
Swedish (3) 3
Afrikaans (1) 1
Breton (1) 1
Dutch (1) 1
Italian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 11/2013, Volume 369, Issue 19, pp. 1807 - 1818
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2015, Volume 373, Issue 8, pp. 705 - 713
Among patients coinfected with HIV-1 and HCV genotype 1 or 4 who were receiving effective antiretroviral therapy, treatment with 12 weeks of ledipasvir and... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | HIV-1 | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Fluorenes - pharmacokinetics | Hepacivirus - isolation & purification | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Benzimidazoles - pharmacokinetics | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | HIV Infections - drug therapy | Uridine Monophosphate - pharmacokinetics | Sofosbuvir | Care and treatment | Research | Hepatitis C virus | HIV infection | Emtricitabine | Headache | Antiretroviral drugs | Inhibitor drugs | Diarrhea | Fatigue | Patients | Efavirenz | Studies | Tenofovir | Cirrhosis | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Hepatitis C | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
Annals of internal medicine, ISSN 0003-4819, 2011, Volume 154, Issue 7, pp. 445 - 456
Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective: To compare time to virologic failure; first grade-3 or -4 sign,... 
Atazanavir | Ritonavir | Research | Drug therapy | Health aspects | Efavirenz | HIV infection
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 09/2018, Volume 67, Issue 5, pp. 785 - 790
Abstract Background A clinical trial showed that efavirenz 400 mg once daily (EFV400) is as effective as the standard adult dose. World Health Organization... 
pharmacokinetics | pregnancy | low-dose efavirenz | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Index Medicus
Journal Article
AIDS care, ISSN 1360-0451, 10/2015, Volume 28, Issue 3, pp. 401 - 408
This 96-week, randomized, open-label study was designed to assess the efficacy and safety of two single-tablet regimens in treatment naïve HIV-1-infected... 
treatment-naive | single-tablet regimen | Antiretroviral therapy | efavirenz | rilpivirine | singletablet regimen | treatmentnaive | Psychology, Multidisciplinary | Social Sciences | Life Sciences & Biomedicine | Psychology | Social Sciences, Biomedical | Respiratory System | Health Care Sciences & Services | Public, Environmental & Occupational Health | Health Policy & Services | Biomedical Social Sciences | Science & Technology | Medication Adherence - statistics & numerical data | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use | Tablets | Humans | Middle Aged | Self Report | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - adverse effects | Emtricitabine, Rilpivirine, Tenofovir Drug Combination - therapeutic use | HIV Infections - psychology | Male | RNA, Viral - blood | Treatment Outcome | Patient Outcome Assessment | HIV-1 - genetics | Viral Load | Emtricitabine, Rilpivirine, Tenofovir Drug Combination - adverse effects | HIV-1 - isolation & purification | Drug-Related Side Effects and Adverse Reactions | Quality of Life | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Discontinued | Drugs | Drug abuse | Transportation safety | Life assessment | Efavirenz | Adherence | Tenofovir | Intestine | Antiretroviral agents | Human immunodeficiency virus--HIV | Safety | Emtricitabine | Antiretroviral drugs | Critical incidents | Diarrhea | Efficacy | Ribonucleic acid--RNA | Adhesion | Patients | Quality of life | Selfreport | Diarrhoea | Adults | Quality assessment | Index Medicus | AIDS/HIV
Journal Article
Organic & biomolecular chemistry, ISSN 1477-0520, 2/2018, Volume 16, Issue 6, pp. 114 - 128
A new series of diarylpyrimidines (DAPYs) were designed, synthesized and evaluated as novel HIV-1 NNRTIs to further explore the chemical space surrounding the... 
Molecular modelling | Molecular structure | Toxicity | Human immunodeficiency virus--HIV | Cytotoxicity | Hydrophobicity | Chemical synthesis | Efavirenz | Optimization | Molecular docking | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2011, Volume 365, Issue 16, pp. 1471 - 1481
Journal Article